PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
    1.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION 审中-公开
    用于口服管理的药物组合物

    公开(公告)号:US20100144711A1

    公开(公告)日:2010-06-10

    申请号:US12568342

    申请日:2009-09-28

    IPC分类号: A61K31/551 A61P7/02

    摘要: A pharmaceutical composition for oral administration, comprising 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof, and hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C., and a process of manufacturing the pharmaceutical composition for oral administration are disclosed.

    摘要翻译: 一种用于口服给药的药物组合物,包含3-羟基-N1-(4-甲氧基苯甲酰基)-N2- [4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰] -1,2-苯二胺或 其药学上可接受的盐和在20℃的2%水溶液中粘度为约6mPa·S(含)至约150mPa·S(独占)的羟丙基纤维素,或粘度为75mPa·S( 包含)至25℃下的5%水溶液中的400mPa·S(含),并且公开了用于口服给药的药物组合物的制造方法。

    Method of producing a structural member
    2.
    发明授权
    Method of producing a structural member 失效
    制造结构件的方法

    公开(公告)号:US5599408A

    公开(公告)日:1997-02-04

    申请号:US232191

    申请日:1994-05-04

    摘要: .epsilon. phase precipitates in the matrix having a composition of 0.07% or less carbon, 1 or less silicon, 1% or less manganese, 2.5 to 5% copper, 3 to 5.5% nickel, 14 to 17.5% chromium, 0.5% or less molybdenum, 0.15 to 0.45% niobium, by weight, and the balance composed substantially of iron, and comprising 6 to 30 vol % austenitic phase and the balance composed substantially of martensitic phase. In a method of producing a structural member in which first solution treatment is performed at 1010.degree. to 1050.degree. C. on a stainless steel having a composition described above and first aging treatment is performed at a temperature not lower than 520.degree. C. and not higher than 630.degree. C., second solution treatment is performed at 730.degree. to 840.degree. C., and then second aging treatment is performed at a temperature not lower than 520.degree. C. and not higher than 630.degree. C. or a structural member of any shape is fabricated by means of welding work before the second solution treatment. Also, a structural member is produced by performing first solution treatment at 1010.degree. to 1050.degree. C. on a stainless steel having a composition described above, performing aging treatment at a temperature not lower than 520.degree. C. and not higher than 630.degree. C., fabricating a structural member of any shape by means of welding work, heating the material at a rate of 100.degree. C./hour or lower, performing second solution treatment at 1010.degree. to 1050.degree. C., cooling the material in a furnace to room temperature at a cooling rate of 100.degree. C./hour or lower, performing aging treatment at a temperature not lower than 520.degree. C. and not higher than 630.degree. C., and cooling the material in a furnace to room temperature at a cooling rate of 100.degree. C./hour or lower.

    摘要翻译: PCT No.PCT / JP93 / 01137 Sec。 371日期:1994年5月4日 102(e)日期1994年5月4日PCT提交1993年8月12日PCT公布。 出版物WO94 / 05824 日期1994年3月17日在基体中的ε相析出物具有0.07%以下的碳,1%以下的硅,1%以下的锰,2.5〜5%的铜,3〜5.5%的镍,14〜17.5%的铬 ,0.5重量%以下的钼,0.15〜0.45重量%的铌,余量基本上由铁构成,并且含有6〜30体积%的奥氏体相,余量基本上由马氏体相组成。 在具有上述组成的不锈钢上,在1010℃〜1050℃进行第一固溶处理的结构体的制造方法中,在不低于520℃的温度下进行第一时效处理 高于630℃,在730℃至840℃进行第二次溶液处理,然后在不低于520℃且不高于630℃的温度下进行第二时效处理或结构构件 任何形状的材料都是在第二次固溶处理之前通过焊接工艺制造的。 此外,通过在具有上述组成的不锈钢上进行1010℃至1050℃的第一次固溶处理,在不低于520℃且不高于630℃的温度下进行时效处理来制造结构件 通过焊接工作制造任何形状的结构件,以100℃/小时或更低的速率加热材料,在1010℃至1050℃进行第二次溶液处理,在炉中冷却材料 以100℃/小时以下的冷却速度进行室温,在不低于520℃且不高于630℃的温度下进行时效处理,并将炉中的材料冷却至室温 冷却速度为100℃/小时以上。